Ironwood Pharmaceuticals | IRWD - Debt


Ironwood Pharmaceuticals reported $583.99M in Debt for its fiscal quarter ending in December of 2024.





Debt Change Date
Acadia Pharmaceuticals USD 50.79M 1.39M Mar/2026
Agios Pharmaceuticals USD 35.74M 4.46M Mar/2026
Akebia Therapeutics USD 46.51M 7.82M Mar/2025
Almirall EUR 342.86M 61.94M Dec/2025
Alnylam Pharmaceuticals USD 1.27B 5.33M Mar/2026
Amarin USD 0 0 Mar/2025
Ardelyx USD 208.26M 653K Mar/2026
Astellas Pharma JPY 565.95B 265.47B Mar/2026
AstraZeneca USD 32.24B 1.68B Jun/2026
Charles River Laboratories USD 3.06B 485.84M Mar/2026
Coherus Biosciences USD 294.92M 1.25M Mar/2025
Emergent BioSolutions USD 903.2M 495.2M Jun/2023
Halozyme Therapeutics USD 2.14B 2.01M Mar/2026
Incyte USD 38.27M 1.16M Jun/2026
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
Karyopharm Therapeutics USD 299.23M 35.14M Dec/2025
Lexicon Pharmaceuticals USD 99.51M 243K Dec/2023
MacroGenics USD 36.51M 500K Mar/2026
Moderna USD 1.3B 7M Mar/2026
Myriad Genetics USD 59.3M 19.7M Mar/2025
Pacira USD 363.12M 4.53M Jun/2026
PTC Therapeutics USD 286.94M 2.42B Mar/2026
Puma Biotechnology USD 89.06M 55.07M Jun/2024
Sarepta Therapeutics USD 1.04B 3.08M Mar/2026
Takeda JPY 4.94T 58.13B Jun/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024